TD Cowen Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $10
Scotiabank Maintains Sage Therapeutics(SAGE.US) With Buy Rating, Maintains Target Price $17
Scotiabank Reaffirms Their Buy Rating on SAGE Therapeutics (SAGE)
Needham Maintains Sage Therapeutics(SAGE.US) With Hold Rating
Sage Therapeutics Analyst Ratings
Raymond James Maintains Sage Therapeutics(SAGE.US) With Hold Rating
Sage Therapeutics Analyst Ratings
H.C. Wainwright Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $25
TD Cowen Downgrades Sage Therapeutics(SAGE.US) to Hold Rating, Cuts Target Price to $10
Baird Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Cuts Target Price to $9
B of A Securities Maintains Underperform on Sage Therapeutics, Lowers Price Target to $6
Scotiabank Maintains Sage Therapeutics(SAGE.US) With Buy Rating, Maintains Target Price $17
A Quick Look at Today's Ratings for Sage Therapeutics(SAGE.US), With a Forecast Between $6 to $25
Sage Therapeutics Is Maintained at Neutral by Baird
SAGE Therapeutics (SAGE) Gets a Hold From TD Cowen
HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Maintains $25 Price Target
SAGE Therapeutics: Downgrade to Sell Amid Pipeline Setbacks and Reduced Price Target
Sage Therapeutics Analyst Ratings
Stifel Maintains Sage Therapeutics(SAGE.US) With Hold Rating
Needham Maintains Sage Therapeutics(SAGE.US) With Hold Rating